Filana Therapeutics, Inc. (FLNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Filana Therapeutics, Inc. (FLNA) has a cash flow conversion efficiency ratio of -0.130x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.88 Million) by net assets ($68.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Filana Therapeutics, Inc. to measure how many days the company can operate on defensive assets alone.
Filana Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Filana Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Filana Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Filana Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Changhong Meiling Co Ltd B
SHE:200521
|
0.403x |
|
ARRAS MINERALS CORP.
F:9RJ
|
-0.066x |
|
Hana Must SPAC 2
KQ:208370
|
0.013x |
|
Formosa Prosonic Industries
KLSE:9172
|
0.009x |
|
M2I Corporation
KQ:347890
|
0.030x |
|
Inhwa Precision Co. Ltd
KQ:101930
|
0.012x |
|
Pansari Developers Limited
NSE:PANSARI
|
0.253x |
|
Selic Corp Public Company Limited
BK:SELIC
|
0.061x |
Annual Cash Flow Conversion Efficiency for Filana Therapeutics, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Filana Therapeutics, Inc. from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see FLNA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $74.40 Million | $-32.25 Million | -0.433x | +45.98% |
| 2024-12-31 | $145.70 Million | $-116.93 Million | -0.803x | -34.49% |
| 2023-12-31 | $137.47 Million | $-82.03 Million | -0.597x | -75.15% |
| 2022-12-31 | $227.54 Million | $-77.51 Million | -0.341x | -- |
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from… Read more